Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1747-1757
DOI: 10.1200/jco.22.00972 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Thomas Yau und 18 weiteren Autor:innen. Beteiligte Einrichtung: The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. METHODS In cohort 6 of the multicohort, open-label, phase I/II CheckMate 040 study, patients who were treatment-naive, sorafenib-intolerant, or had progressed on sorafenib were randomly assigned 1:1 to nivolumab 240 mg once every 2 weeks plus cabozantinib 40 mg once daily (doublet arm); or nivolumab 3 mg/kg every 2 weeks plus cabozantinib 40 mg once daily with ipilimumab 1 mg/kg once every 6 weeks (triplet arm). Primary objectives were safety and tolerability, objective response rate, and duration of response by investigator assessment per RECIST v1.1. Secondary objectives included progression-free survival (by blinded independent central review) and overall survival. RESULTS Seventy-one patients were randomly assigned: 36 to the doublet arm and 35 to the triplet arm. After 32.0-month median follow-up, objective response rate (95% CI) was 17% (6 to 33) and 29% (15 to 46) in the doublet and triplet arms, respectively. Median (95% CI) duration of response was 8.3 (6.9 to not estimable) months in the doublet arm and not reached (0.0 to not estimable) in the triplet arm. Median progression-free survival was 5.1 and 4.3 months, and median overall survival was 20.2 and 22.1 months for the doublet and triplet arms, respectively. Grade 3-4 treatment-related adverse events occurred in 50% and 74% of patients and treatment-related adverse events leading to discontinuation were reported for 11% and 23% in the doublet and triplet arms, respectively. There were no treatment-related deaths in either arm. CONCLUSION Nivolumab plus cabozantinib with or without ipilimumab showed encouraging preliminary antitumor activity and had consistent safety profiles with those established for the individual drugs in patients with advanced hepatocellular carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Hong Kong, Hong Kong, China.
- Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- IRCCS Humanitas Research Hospital-Humanitas Cancer Center, Rozzano, Italy.
- Fundacion de Investigación, San Juan, Puerto Rico.
- National Cancer Center and Curie Oncology, Singapore.
ORCID-Profile: Thomas Yau, Armando Santoro, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Anthony B El-Khoueiry, Bruno Sangro, Gina M Vaccaro
Zitieren
APA
Yau, T., Zagonel, V., Santoro, A., Acosta-Rivera, M., Choo, S. P., Matilla, A., He, A. R., Cubillo Gracian, A., El-Khoueiry, A. B., Sangro, B., Eldawy, T. E., Bruix, J., Frassineti, G. L., Vaccaro, G. M., Tschaika, M., Scheffold, C., Koopmans, P., Neely, J., & Piscaglia, F. (2023). Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology, 41(9), 1747-1757. https://doi.org/10.1200/jco.22.00972
Vancouver
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, et al. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology. 2023;41(9):1747-1757. doi:10.1200/jco.22.00972
BibTeX
@article{Yau2023,
author = {Yau, Thomas and Zagonel, Vittorina and Santoro, Armando and Acosta-Rivera, Mirelis and Choo, Su Pin and Matilla, Ana and He, Aiwu Ruth and Cubillo Gracian, Antonio and El-Khoueiry, Anthony B and Sangro, Bruno and Eldawy, Tarek E and Bruix, Jordi and Frassineti, Giovanni Luca and Vaccaro, Gina M and Tschaika, Marina and Scheffold, Christian and Koopmans, Petra and Neely, Jaclyn and Piscaglia, Fabio},
title = {Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {9},
pages = {1747--1757},
doi = {10.1200/jco.22.00972}
}
EUVIMED